Skip to main content

Abstract

This deals with regulatory frameworks for biomedical technologies generally, and pre-implantation genetic interventions more specifically. In doing so, the chapter highlights some of the challenges in attempting to effectively regulate biomedical technologies that move at the pace of lightning speed. In addition, the chapter proposes the use of a combination of regulatory approaches, in complementarity with existing legal frameworks, to consider building a more flexible and reflexive form of governance for biomedical technologies. Further clarity may also be had in examining the development of the regulatory frameworks in the abortion debates and earlier prenatal testing technologies. These are discourses that bear a close nexus to pre-implantation genetic interventions and may impart the values and modalities in these debates to complement the role of the law or legal framework in a regulatory environment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    History ‘The 1960s - Facts & Summary’ ( history.com ) http://www.history.com/topics/1960s.

  2. 2.

    Anthony J. Pennings, ‘Arthur C. Clarke’s Three Laws of Innovation’ Writings on Digital Strategies, ICT Economies, and Global Communications (1 July 2012), http://apennings.com/political-economies-in-sf/arthur-c-clarkes-three-laws-of-innovation/.

  3. 3.

    The Guardian, ‘Profiles of the Future by Arthur C Clarke – Review’ The Guardian (4 March 2011) https://www.theguardian.com/science/2011/mar/04/profiles-future-arthur-clarke-review.

  4. 4.

    Clarke (1985).

  5. 5.

    ibid.

  6. 6.

    Finnis (2015), p. 199.

  7. 7.

    Brownsword and Yeung (2008), p. 5.

  8. 8.

    Esther Inglis-Arkell, ‘Technology Isn’t Magic: Why Clarke’s Third Law Always Bugged Me’ io9 (28 April 2013) http://io9.gizmodo.com/technology-isnt-magic-why-clarkes-third-law-always-bug-479194151.

  9. 9.

    Lessig (1999), p. 43.

  10. 10.

    ibid 6.

  11. 11.

    Brownsword and Yeung (2008), p. 5.

  12. 12.

    ibid 3.

  13. 13.

    Jonathan Freedland, ‘1984 by George Orwell, Book of a Lifetime: An Absorbing, Deeply Affecting Political Thriller’ The Independent (2 July 2015) http://www.independent.co.uk/arts-entertainment/books/reviews/1984-by-george-orwell-book-of-a-lifetime-an-absorbing-deeply-affecting-political-thriller-10360789.html.

  14. 14.

    Johan Norberg, ‘Why Can’t We See That We’re Living in a Golden Age?’ The Spectator (20 August 2016) https://www.spectator.co.uk/2016/08/why-cant-we-see-that-were-living-in-a-golden-age/.

  15. 15.

    Brownsword and Goodwin (2012), pp. 24–25.

  16. 16.

    ibid 25. See also Black (2005), p. 11.

  17. 17.

    Mandel (2009), pp. 75, 76.

  18. 18.

    Lessig (1999), p. 5. It is interesting at this juncture to note that Lessig did not mean “constitution” to refer to a legal text in the manner of the United States Constitution. Instead, Lessig refers to an alternative interpretation of “constitution” that is equated with a “way of life”.

  19. 19.

    ibid.

  20. 20.

    Brownsword (2011), p. 207.

  21. 21.

    ibid 208.

  22. 22.

    Nelson and Oxley (1999), p. 1040.

  23. 23.

    ibid 1041.

  24. 24.

    Nelson and Oxley (1999).

  25. 25.

    Inhorn (2003), p. 1837.

  26. 26.

    Nemudryi et al. (2014), p. 22.

  27. 27.

    Carroll (2011), p. 773.

  28. 28.

    Stock (2005), p. 27.

  29. 29.

    Foucault (1977).

  30. 30.

    Liebert and Schmidt (2010), p. 55. See also: Brownsword and Yeung (2008). I found it compelling to give mention to the issue of the Collingridge Dilemma, which was raised by Browsword in Rights, Regulation and the Technological Revolution. The basis of the Collingridge Dilemma is essentially a trade-off process: between regulating technologies while they are still new, and their future consequences may be projected; or waiting to see how the technologies will develop over a given period of time, but then losing the ability to control the manner in which it may be regulated.

  31. 31.

    Brownsword (2011), p. 208.

  32. 32.

    Level Crossings, Law Commission Consultation Paper No. 194, Scottish Law Commission and Law Commission Discussion Paper No. 143, ‘Regulatory Theory’ (2010) https://www.scotlawcom.gov.uk/files/5312/8024/5698/regulatory_theory.pdf.

  33. 33.

    ibid.

  34. 34.

    This is particularly accurate because of the global economic slump and boom in the late 1960s period, which led to the approach of “regulation theory”, a derivative of Marxist economic theory as a means of dealing with capitalism, a shift in the industrial regime, and development in society. However, regulatory theory is not the same as “regulation” theory, although it may be said that the underlying purposes of these theories address the linkage between legal, social, cultural and political contexts.

  35. 35.

    Ayres and Braithwaite (1992).

  36. 36.

    Baldwin and Cave (1999).

  37. 37.

    ibid.

  38. 38.

    Drahos (2017).

  39. 39.

    ibid 3–4.

  40. 40.

    ibid 4.

  41. 41.

    ibid.

  42. 42.

    Thomas Hobbes, Leviathan or the Matter, Forme, & Power of a Common-Wealth Ecclesiasticall and Civill. (Andrew Crooke at the Green Dragon in St Paul’s Church-yard 1651) https://socialsciences.mcmaster.ca/econ/ugcm/3ll3/hobbes/Leviathan.pdf.

  43. 43.

    Drahos (2017), p. 12.

  44. 44.

    ibid 14.

  45. 45.

    Foucault and Gordon (1980), p. 98.

  46. 46.

    Drahos (2017), p. 17.

  47. 47.

    ibid 16.

  48. 48.

    Braithwaite (2017b), p. 28.

  49. 49.

    ibid 26.

  50. 50.

    ibid 27.

  51. 51.

    ibid 29.

  52. 52.

    ibid. Braithwaite further refers to the work of Meidinger (1987), pp. 355–386. A ‘regulatory community’ is one where there are groups of regulatory actors comprised through “different subcultural groups with their own values, normal, beliefs and processes.” The idea of a ‘regulatory community’ is that it is powerful enough to either support by extension, or even undermine, regulatory authorities.

  53. 53.

    Hume (1896).

  54. 54.

    Drahos (2017), p. 17.

  55. 55.

    ibid 16.

  56. 56.

    ibid 18.

  57. 57.

    Ayres and Braithwaite (1992).

  58. 58.

    OECD, ‘Biomedicine and Health Innovation: Synthesis Report’ (2010) http://www.oecd.org/health/biotech/46925602.pdf.

  59. 59.

    ibid 14.

  60. 60.

    ibid 15.

  61. 61.

    ibid 17.

  62. 62.

    ibid 18.

  63. 63.

    These international instruments will be more specifically expanded on in Chap. 5.

  64. 64.

    UNESCO, ‘Universal Declaration on the Human Genome and Human Rights (11 November 1997)’ http://portal.unesco.org/en/ev.php-URL_ID=13177&URL_DO=DO_TOPIC&URL_SECTION=201.html.

  65. 65.

    UNESCO, ‘The Universal Declaration on Bioethics and Human Rights (2006)’ http://unesdoc.unesco.org/images/0014/001461/146180E.pdf.

  66. 66.

    Conseil de l’Europe, Convention for the Protection of Human Rights and Dignity of the Human Being with Regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine (Editions du Conseil de l’Europe 1997) http://193.205.211.30/lawtech/images/lawtech/law/convenzioneoviedo.pdf.

  67. 67.

    European Medicines Agency, ‘Report of the EMA Expert Meeting on Genome Editing Technologies Used in Medicinal Product Development’ (European Medicines Agency 2018) EMA/47066/2018.

  68. 68.

    European Commission JRC Science for Policy, ‘JRCF7- Knowledge Health and Consumer Safety, Overview of EU National Legislation on Genomics’ (European Commission 2018) EUR29404EN http://publications.jrc.ec.europa.eu/repository/bitstream/JRC113479/policy_report_-_review_of_eu_national_legislation_on_genomics_-_with_identifiers.pdf.

  69. 69.

    World Medical Association, ‘WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects’ (19 October 2013) https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/.

  70. 70.

    Kleinlein (2012), p. 703.

  71. 71.

    This does not mean that I do not accept the universality of some common values and legal norms that are recognized in international law. However, the rhetoric of the “Asian values” principles which may, in the past, sometimes been unfairly categorized as the negative aspects of cultural relativism, can provide some insight into the contemporary motivations that influence regulation-shaping in some Asian countries.

  72. 72.

    Harmon (2016), p. 680.

  73. 73.

    ibid 681.

  74. 74.

    ibid 683.

  75. 75.

    Although Harmon’s article appears to focus on precision or personalized medicine, and biobanking/data sharing, the import of the components he has suggested have the aim of ensuring the biomedical regulation are timely, critical, safe and effective.

  76. 76.

    Harmon (2016), p. 684.

  77. 77.

    ibid 685.

  78. 78.

    ibid.

  79. 79.

    ibid.

  80. 80.

    ibid 683. Harmon refers to LF as “a future oriented process aimed at identifying and exploring possible and desirable legal or quasi-legal interventions directed at better achieving valued social and technological ends.”

  81. 81.

    ibid 682., March 10, 2016, and Shawn H.E. Harmon ‘Evidence, Engagement and Transparency in Decision-Making’, presented at Canadian Centre for Vaccinology, June 10, 2016.

  82. 82.

    Laurie et al. (2012), p. 1.

  83. 83.

    Harmon (2016), p. 682.

  84. 84.

    Ayres and Braithwaite (1992). This responsive approach also includes the exercise of a ‘soft law’ approach and self-governance regulatory mechanisms. In Section 4.1.3 of this chapter, p. 185, I provide further illustration on this regulatory approach and how it may benefit the fluid nature of biomedical technologies and yet achieve a necessary balance from a legal perspective.

  85. 85.

    Scottish Law Commission and Law Commission (2010). The smart regulation approach is a multi-level, multi-lateral regulatory approach that employs a broad range of tools in regulation, and reaches multiple layers of stakeholders that are relevant to the regulatory dynamics of the system.

  86. 86.

    Van Klink (2016).

  87. 87.

    Poort et al. (2016), p. 1.

  88. 88.

    Ayres and Braithwaite (1992).

  89. 89.

    Parker (2013), p. 2, 2.

  90. 90.

    Nielsen and Parker (2009), p. 376.

  91. 91.

    ibid 379.

  92. 92.

    ibid 378.

  93. 93.

    Ayres and Braithwaite (1992), p. 39. Please see: Figure 2.3, p. 39.

  94. 94.

    Parker (2013), p. 4. Please see also: Braithwaite (2002).

  95. 95.

    ibid. Please see also: Braithwaite and Drahos (2000).

  96. 96.

    Braithwaite (2017a), p. 117.

  97. 97.

    Ayres and Braithwaite (1992), p. 40.

  98. 98.

    ibid 39.

  99. 99.

    Engeli and Rothmayr (2016), p. 248.

  100. 100.

    ibid 249.

  101. 101.

    ibid.

  102. 102.

    Gunningham et al. (1998).

  103. 103.

    Gunningham and Sinclair (2017).

  104. 104.

    ibid 139.

  105. 105.

    ibid 135.

  106. 106.

    ibid 140.

  107. 107.

    ibid 141.

  108. 108.

    ibid 140.

  109. 109.

    ibid 141.

  110. 110.

    ibid 145.

  111. 111.

    Please see: Baldwin and Black (2008), pp. 59–94; Bocher, M and Toller, AE 2003. Conditions for the emergence of alternative environmental policy instruments, paper presented at the Second European Consortium of Political Research Conference, Marburg, Germany, 18–21 September. Some of the criticism leveled against smart regulation is that it fails to take into account and address “institutional issues, compliance type specific responses, performance sensitivity and adaptability of regulatory regimes.”

  112. 112.

    Gunningham and Sinclair (2017), p. 145. Gunningham and Sinclair refer to van Gossum et al. (2010), pp. 245–261.

  113. 113.

    van Klink (2016).

  114. 114.

    ibid.

  115. 115.

    ibid 22.

  116. 116.

    Poort et al. (2016), p. 3.

  117. 117.

    ibid.

  118. 118.

    ibid 4.

  119. 119.

    Harryono et al. (2006). See also: Mohd Mutalip (2012), p. 1.

  120. 120.

    Brownsword and Yeung (2008), p. 373.

  121. 121.

    ibid 367.

  122. 122.

    ibid 373–381.

  123. 123.

    Brownsword (2011), p. 209.

  124. 124.

    Posner (2006), p. 1049.

  125. 125.

    Sajó and Ryan (2016), p. 3.

  126. 126.

    ibid 4.

  127. 127.

    ibid 8.

  128. 128.

    Brownsword (2008), pp. 31–131.

  129. 129.

    ibid 31.

  130. 130.

    ibid 35.

  131. 131.

    ibid 70.

  132. 132.

    ibid 100.

  133. 133.

    Brownsword (2008), p. 209.

  134. 134.

    ibid.

  135. 135.

    ibid. See also (n 44).

  136. 136.

    Brownsword (2008), p. 24.

  137. 137.

    ibid 273.

  138. 138.

    ‘The Universal Declaration on Bioethics and Human Rights’ (2006).

  139. 139.

    Brownsword (2008), p. 35.

  140. 140.

    ibid.

  141. 141.

    ibid 31.

  142. 142.

    Burns (2005), p. 46.

  143. 143.

    ‘The Universal Declaration on Bioethics and Human Rights’ (2006). Article 4 states: “In applying and advancing scientific knowledge, medical practice and associated technologies, direct and indirect benefit to patients, research participants and other affected individuals should be maximized and any possible harm to such individuals should be minimized.”

  144. 144.

    Bentham et al. (1988).

  145. 145.

    Brownsword (2008), p. 37.

  146. 146.

    ibid 36.

  147. 147.

    ibid 37.

  148. 148.

    ‘The Universal Declaration on Bioethics and Human Rights’ (2006). Article 3(2) of the Declaration stipulates that “the interests and welfare of the individual should have priority over the sole interest of science or society.”

  149. 149.

    Brownsword (2008), p. 37.

  150. 150.

    ibid.

  151. 151.

    ibid 39.

  152. 152.

    ibid.

  153. 153.

    ibid.

  154. 154.

    Francioni (2007), p. 50.

  155. 155.

    Brownsword (2008), p. 39.

  156. 156.

    Francioni (2007), p. 51.

  157. 157.

    Brownsword (2008), p. 41.

  158. 158.

    ibid.

  159. 159.

    ibid 42–43.

  160. 160.

    Brownsword (2008), p. 43.

  161. 161.

    Schloendorff v The Society of the New York Hospital (1914) 211 NY 125 (The Court of Appeals of New York).

  162. 162.

    Aveyard (2002), p. 201.

  163. 163.

    Airedale NHS Trust v Bland [1993] AC 789, p. 864 per Lord Goff: “…The principle of self determination requires that respect must be given to the wishes of the patient…..the principle of the sanctity of human life must yield to the principle of self-determination…and…the physician’s duty to act in the best interests of his patient must likewise be qualified.”

  164. 164.

    Brownsword (2008), p. 71.

  165. 165.

    ‘The Universal Declaration on Bioethics and Human Rights’ (2006). See Article 6.1 and Article 6.2 of the Declaration, which provides for the “prior, free and informed consent of the person concerned”, whether in connection to any medical intervention or scientific research.

  166. 166.

    Brownsword (2008), p. 70.

  167. 167.

    ibid 75. Here, Brownsword also refers to Beyleveld and Brownsword (2007).

  168. 168.

    ibid 102. We will find, that in looking at the challenge of legitimacy in pluralistic environments, where questions about the meaning of ‘harm’ and the precautionary principle has to be balanced on an equal footing, the positioning of views and perspectives within the bioethical triangle is once again considered.

  169. 169.

    ibid 98.

  170. 170.

    ibid 24. See also (n 49) and (n 50).

  171. 171.

    ibid 92.

  172. 172.

    ibid 87.

  173. 173.

    ibid 100.

  174. 174.

    ibid.

  175. 175.

    ibid 101.

  176. 176.

    Peter (2008), p. 33.

  177. 177.

    Brownsword (2008), p. 101.

  178. 178.

    Peter (2008), p. 33.

  179. 179.

    Brownsword (2008), p. 101.

  180. 180.

    ten Have and Jean (2009).

  181. 181.

    Brownsword (2008), p. 102.

  182. 182.

    ibid 102–105. Brownsword elaborates on the employability of the meaning of ‘harm’ in the context of the pluralistic perspectives of the bioethical triangle, encompassing the human rights perspective, the utilitarian view and the dignitarian standards. The determination of ‘harm’ in these varying ethical viewpoints further contributes to the difficulty of pluralism, as an additional layer of determinative considerations.

  183. 183.

    ‘The Universal Declaration on Bioethics and Human Rights’ (2006). Article 17 states: “Due regard is to be given to the interconnection between human beings and other forms of life, to the importance of appropriate access and utilization of biological and genetic resource, to respect for traditional knowledge and to the role of human beings in the protection of the environment, the biosphere and biodiversity.”

  184. 184.

    ten Have and Jean (2009).

  185. 185.

    Brownsword (2008), p. 132.

  186. 186.

    ibid.

  187. 187.

    ibid 133.

  188. 188.

    ibid 134.

  189. 189.

    Biegel (2001).

  190. 190.

    ibid 353–364.

  191. 191.

    Brownsword (2008), p. 145.

  192. 192.

    ibid 146.

  193. 193.

    ibid 138.

  194. 194.

    ibid.

  195. 195.

    ibid 139–150.

  196. 196.

    ibid 139.

  197. 197.

    ibid.

  198. 198.

    ibid 140.

  199. 199.

    ibid 141.

  200. 200.

    ibid 142.

  201. 201.

    Bimber (1990), p. 333.

  202. 202.

    ibid 335.

  203. 203.

    Phillips (1995), p. 5.

  204. 204.

    Dafoe (2015), p. 1047.

  205. 205.

    ibid 1050.

  206. 206.

    ibid.

  207. 207.

    Kant (2003).

  208. 208.

    Dafoe (2015), p. 1051.

  209. 209.

    ibid 1054.

  210. 210.

    Brownsword (2008), p. 160.

  211. 211.

    ibid.

  212. 212.

    Fuller (1969).

  213. 213.

    Brownsword (2008), p. 161.

  214. 214.

    ibid 160.

  215. 215.

    Fuller (1969).

  216. 216.

    Ribeiro (2001), p. 2842.

  217. 217.

    Brownsword (2008), p. 185.

  218. 218.

    ibid 186.

  219. 219.

    ibid.

  220. 220.

    Somek (2014).

  221. 221.

    Brownsword (2008), p. 186.

  222. 222.

    Somek (2014), p. 242.

  223. 223.

    ibid 22–23.

  224. 224.

    Brownsword (2008), p. 187.

  225. 225.

    Uitz (2015), p. 279.

  226. 226.

    Jan-Werner Müller, ‘The Problem with Poland’ The New York Review of Books (11 February 2016) http://www.nybooks.com/daily/2016/02/11/kaczynski-eu-problem-with-poland/ See also Christian Keszthelyi, ‘Government’s “Stop Brussels” Campaign Revs Up’, Budapest Business Journal (2 May 2017) http://bbj.hu/politics/governments-stop-brussels-campaign-revs-up_132259.

  227. 227.

    Somek (2014), p. 22.

  228. 228.

    Patterson et al. (2015), p. 667, 676.

  229. 229.

    Somek (2014), p. 253.

  230. 230.

    Galen Strawson, ‘Sapiens: A Brief History of Humankind by Yuval Noah Harari – Review’ The Guardian (11 September 2014) https://www.theguardian.com/books/2014/sep/11/sapiens-brief-history-humankind-yuval-noah-harari-review.

  231. 231.

    Harari (2015), p. 162.

  232. 232.

    Harari (2015).

  233. 233.

    ibid 246.

  234. 234.

    ibid 274.

  235. 235.

    ibid 266.

  236. 236.

    Gibbs (2014), p. 168. Project Gilgamesh, deriving its name from the ‘Epic of Gilgamesh’, the mythical King of Uruk, is an initiative that is focused on the extension of human life and the control of human aging through scientific and medical technologies. Similar to the SENS Research Foundation project on aging, Project Gilgamesh advocates the use of science, cryonics and other methods for radical life extension as its key moral imperatives. See also: http://www.projectgilgamesh.com/what-is-project-gilgamesh/.

  237. 237.

    Trebilcock and Iacobucci (2009), p. 455, 457.

  238. 238.

    Liebert and Schmidt (2010).

  239. 239.

    Collingridge (1982).

  240. 240.

    ‘Roe v. Wade, 410 U.S. 113 (1973)’ (Justia Law) https://supreme.justia.com/cases/federal/us/410/113/.

  241. 241.

    Callahan (1986), p. 33.

  242. 242.

    ibid 33.

  243. 243.

    ibid 34.

  244. 244.

    Cannon (1991), p. 812.

  245. 245.

    Stacie Taranto, ‘How Abortion Became the Single Most Important Litmus Test in American Politics’ The Washington Post (22 January 2018) https://www.washingtonpost.com/news/made-by-history/wp/2018/01/22/how-abortion-became-the-single-most-important-litmus-test-in-american-politics/?noredirect=on&utm_term=.b4015648272b.

  246. 246.

    Noonan (1977), p. 29.

  247. 247.

    Lee, Michelle Yee Hee, ‘Donald Trump’s Claim He Evolved into “pro-Life” Views, like Ronald Reagan’ The Washington Post (31 March 2016) https://www.washingtonpost.com/news/fact-checker/wp/2016/03/31/donald-trumps-claim-he-evolved-into-pro-life-views-like-ronald-reagan/?noredirect=on&utm_term=.a98e5a4e62f8.

  248. 248.

    Megan Farokhmanesh, ‘How a Trump Administration Threatens Women’s Health’, The Verge (12 December 2016) https://www.theverge.com/2016/12/12/13904032/trump-womens-reproductive-health-affordable-care-planned-parenthood.

  249. 249.

    Jon Kelly, ‘Why Are Northern Ireland’s Abortion Laws Different?’ BBC News (8 April 2016) http://www.bbc.com/news/magazine-35980195.

  250. 250.

    Case of A, B and C v Ireland [2010] Grand Chamber 25579/05.

  251. 251.

    BBC, ‘Abortion “Would Have Saved Wife”’ BBC News (14 November 2012) http://www.bbc.com/news/uk-northern-ireland-20321741.

  252. 252.

    Allison O’Connor, ‘How the Death of Savita Halappanavar Changed the Abortion Debate’, The Irish Examiner (28 October 2017) http://www.irishexaminer.com/analysis/how-the-death-of-savita-halappanavar-changed-the-abortion-debate-461787.html.

  253. 253.

    Tom Gotsis and Laura Ismay, ‘Abortion Law: A National Perspective, Briefing Paper No. 2/2017’ NSW Parliamentary Research Service https://www.parliament.nsw.gov.au/researchpapers/Documents/Abortion%20Law.pdf.

  254. 254.

    In other Australian states, abortion is legal up until a period of time, or such other expressly stipulated condition in the relevant State statutes. For example, in the Australian Capital Territory and South Australia, abortion is legal if medically agreed upon by 2 doctors that it would be necessary for the benefit of the woman’s physical or mental health. In Victoria, Tasmania, Western Australia and the Northern Territory, abortion is legal up until a specified period of time, after which special considerations may apply.

  255. 255.

    International Women’s Development Agency (IWDA) ‘Reproductive Rights, Abortion & Zoe’s Law: Why Freedom of Choice Is Still Feminism’s Biggest Fight’ (26 April 2015) https://iwda.org.au/reproductive-rights-abortion-zoes-law-why-freedom-of-choice-is-still-feminisms-biggest-fight/.

  256. 256.

    Crimes Amendment (Zoe’s Law) Bill 2017 https://www.parliament.nsw.gov.au/bills/Pages/bill-details.aspx?pk=2936.

  257. 257.

    Christina M.H. Powell, ‘Being Human: How Should We Define Life and Personhood?’ Enrichment Journal http://enrichmentjournal.ag.org/201002/201002_134_define_person.cfm.

  258. 258.

    Crimes Amendment (Zoe’s Law) Bill 2017 (n 256).

  259. 259.

    Jenny Noyes, ‘On Zoe’s Law, And The Accidental/On Purpose Erosion Of Your Reproductive Rights’ Junkee (21 November 2013) http://junkee.com/on-zoes-law-and-the-accidentalon-purpose-erosion-of-your-reproductive-rights/21659.

  260. 260.

    ibid.

  261. 261.

    Crimes Amendment (Zoe’s Law) Bill 2017 (n 256).

  262. 262.

    Kelsey Munro, ‘Fred Nile Gives Renewed Push to Zoe’s Law to Criminalise Harm to a Fetus’, Sydney Morning Herald (10 March 2017) http://www.smh.com.au/nsw/fred-nile-gives-renewed-push-to-zoes-law-to-criminalise-harm-to-a-fetus-20170309-guup40.html.

  263. 263.

    Callahan (1986).

  264. 264.

    ibid 34.

  265. 265.

    ibid 35.

  266. 266.

    ibid 38.

  267. 267.

    Erdman (2015), p. 39.

  268. 268.

    ibid.

  269. 269.

    Callahan (1986), p. 34.

  270. 270.

    Kamel (2013), p. 156.

  271. 271.

    Suter (2002), p. 233.

  272. 272.

    ibid 235.

  273. 273.

    National Human Genome Research Institute (NHGRI) ‘An Overview of the Human Genome Project’ https://www.genome.gov/12011238/an-overview-of-the-human-genome-project/.

  274. 274.

    Suter (2002), p. 252.

  275. 275.

    Nuffield Council on Bioethics, Non-Invasive Prenatal Testing: Ethical Issues (2017).

  276. 276.

    ibid.

  277. 277.

    ibid 2.

  278. 278.

    The NHS is the UK’s National Health Service under the Department of Health and Social Care. It is an executive but non-governmental public body that is primarily tasked with the management, sustainability and development of health care in the UK.

  279. 279.

    Nuffield Council on Bioethics (2017), p. 2.

  280. 280.

    ibid.

  281. 281.

    The scope of PGD services is presently being regulated under the purview of the Human Fertilisation and Embryology Authority in the UK.

  282. 282.

    Nuffield Council on Bioethics, Genome Editing: An Ethical Review (2016).

  283. 283.

    ibid 117.

  284. 284.

    Maturo (2012), p. 122.

  285. 285.

    Parens (2013), p. 28.

  286. 286.

    Morrison (2016), p. 720.

  287. 287.

    Sanders (2017), p. 14. The reality however is that at present, there appears to be at least 52 identifiable genes that are linked to human intelligence and these do not work in isolation, but with each other. As such, it is not yet possible at this juncture to simply “edit” the relevant genes that influence human intelligence because an alteration to one gene linking intelligence is likely to influence another linked human intelligence gene. Nevertheless, the prospect of such possibilities in the future should, in any event, be considered.

  288. 288.

    Sandel (2004), p. 51. Sandel provides illustrative examples of athletes and questions the significance between ‘doping’ in sports and genetic enhancements to improve athletic prowess.

  289. 289.

    Bell (2016), p. 39.

  290. 290.

    ibid 44.

  291. 291.

    Parens (2013), p. 29.

  292. 292.

    ibid 35.

  293. 293.

    Trebilcock and Iacobucci (2009), p. 455.

  294. 294.

    ibid 457. Foreword, p. vii.

  295. 295.

    ibid 458.

  296. 296.

    ibid 459.

  297. 297.

    Brownsword (2008).

  298. 298.

    ‘United States v. Carolene Products Co. 304 U.S. 144 (1938)’ (Justia Law) https://supreme.justia.com/cases/federal/us/304/144/case.html.

  299. 299.

    Exploring Constitutional Conflicts, ‘Levels of Scrutiny Under the Equal Protection Clause’ http://law2.umkc.edu/faculty/projects/ftrials/conlaw/epcscrutiny.htm.

  300. 300.

    Sweet and Mathews (2008), p. 72.

  301. 301.

    Barak (2012), p. 131.

  302. 302.

    ibid.

  303. 303.

    ibid.

  304. 304.

    Stockholm Resilience Centre, ‘Adaptive Governance’ (6 December 2010) http://www.stockholmresilience.org/research/research-streames/stewardship/adaptive-governance-.html.

  305. 305.

    ibid.

  306. 306.

    Chaffin et al. (2014), p. 56.

  307. 307.

    ibid.

  308. 308.

    ibid.

  309. 309.

    ibid.

  310. 310.

    Trebilcock and Iacobucci (2009), p. 460.

  311. 311.

    ibid.

  312. 312.

    ibid 461.

  313. 313.

    ibid 462.

  314. 314.

    ibid.

  315. 315.

    ibid 463.

  316. 316.

    ibid 464.

  317. 317.

    ibid.

  318. 318.

    Lessig (1997), p. 181.

  319. 319.

    ibid 181.

  320. 320.

    Lessig (1999).

  321. 321.

    Lessig (1997).

  322. 322.

    ibid.

  323. 323.

    Brownsword (2008), p. 13.

  324. 324.

    ibid.

  325. 325.

    Lessig (1999), p. 87.

  326. 326.

    ibid 88.

  327. 327.

    Lessig (2006), p. 4.

  328. 328.

    ibid.

  329. 329.

    ibid.

  330. 330.

    Lessig (2001).

  331. 331.

    Cosens et al. (2017), p. 30.

  332. 332.

    Dietz et al. (2003), p. 1907.

  333. 333.

    ibid 1908.

  334. 334.

    ibid.

  335. 335.

    Foucault and Gordon (1980).

  336. 336.

    Dietz et al. (2003).

  337. 337.

    ibid 1909.

  338. 338.

    ibid.

  339. 339.

    Cosens et al. (2017), p. 32.

  340. 340.

    ibid.

  341. 341.

    ibid 33.

  342. 342.

    ibid 35.

  343. 343.

    ibid.

  344. 344.

    Brownsword and Goodwin (2012), p. 27.

  345. 345.

    ibid.

  346. 346.

    ibid 26.

References

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lau, P.L. (2019). The Regulatory Framework in Biomedical Technologies. In: Comparative Legal Frameworks for Pre-Implantation Embryonic Genetic Interventions. Springer, Cham. https://doi.org/10.1007/978-3-030-22308-3_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-22308-3_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-22307-6

  • Online ISBN: 978-3-030-22308-3

  • eBook Packages: Law and CriminologyLaw and Criminology (R0)

Publish with us

Policies and ethics